Baker Bros. Advisors 13F: Adds $2.8M to WVE Stake

Baker Bros. Advisors significantly increased its position in Wave Life Sciences Ltd. (NASDAQ: WVE) during the first quarter of 2026. According to its latest Form 13F filing with the Securities and Exchange Commission, the institutional investor added 478,575 shares of the biotechnology firm. This transaction represents a 139.095% increase in the fund's total holdings of the company. The firm ended the filing period on May 15, 2026, holding 822,638 shares valued at approximately $4.78 million.

Baker Bros. Expands Biotech Bet

The recent purchase more than doubled Baker Bros. Advisors' prior position of 344,063 shares of the Cambridge, Massachusetts-based company. The total value of the investment reached about $4.78 million by the end of the reporting period. It is important to remember that Form 13F filings are backward-looking documents that show holdings as of a specific date, meaning the fund may have altered its investment in the stock since the filing was submitted.

Wave Life Sciences Stock Performance

Shares of the company closed at $5.81 on Sunday. The stock has experienced considerable volatility over the last year, trading between a low of $4.20 and a high of $21.73. At the current price of $5.81, the stock trades slightly above its 50-day moving average of $5.32, but remains well below its 200-day moving average of $9.17. The company's total market capitalization currently stands at $839.43 million.

Recent Earnings

For its most recent quarter, Wave Life Sciences reported revenue of $65.37 million, which represents a 73.9% decline compared to the same period in the prior year. The company is currently not profitable, posting an earnings per share loss of $1.08 and a negative return on equity of 67.4%. Because of these losses, the company does not have a meaningful price-to-earnings ratio. Investors are looking forward to the next quarterly financial report, which is scheduled for November 9, 2026.

Analysts Set New Price Targets

Wall Street analysts have actively updated their outlooks on the biotechnology stock. On October 16, 2026, William Blair initiated coverage on the company, issuing an Outperform rating. Just one day prior, on October 15, 2026, UBS started its own coverage with a Buy rating and set an $11.00 price target. Ladenburg Thalmann also issued a Buy rating with a $10.00 price target on October 1, 2026.

Some firms have taken a more cautious stance or lowered their expectations. JP Morgan downgraded the stock to Neutral on September 23, 2026. Earlier in the summer, Mizuho maintained an Outperform rating on August 4, 2026, but reduced its price target to $23.00 from $27.00. On July 31, 2026, Citigroup kept its Buy rating but lowered its target to $19.00 from $24.00, B. Riley Securities maintained a Buy rating with a $22.00 price target, and Wedbush kept its Outperform rating while adjusting its price target down to $12.00. Across 17 analyst opinions, the stock maintains a consensus of strong buy with a mean price target of $18.53.

Developing RNA Medicines

Wave Life Sciences is a clinical-stage biotechnology company that designs and develops genetic medicines. The company utilizes its proprietary PRISM platform to target various rare and chronic disorders, including programs focused on obesity and liver diseases.

What to Watch at Wave Life Sciences Ltd.

Investors will want to track whether other major healthcare-focused investment funds show similar interest in the stock in upcoming filing periods. The company's next major milestone will likely be its upcoming financial and clinical trial updates, scheduled for release on November 9, 2026.